 Greenwich Lifesciences Inc NASDAQ: GLSI shares are trading higher by 32.95 to 11.46 Tuesday afternoon after the FDA removed the clinical hold on the companys Flamingo-01 Phase 3 trial of GP2. Greenwich Lifesciences says through discussions with the FDA and testing of GP2 in the. 